ライフサイエンスコーパス: post-menopausal

1 premenopausal (age < 50 years) and 357 were post- menopausal.

2 emale mice and pre- (42.3 +/- 0.5 years) and post-menopausal (61.9 +/- 0.9 years) women.

3 ose-response associations in endometrial and post-menopausal breast cancer, and in degree and duratio

4 with ABS compared with patients with MI and post-menopausal controls (p < 0.05).

5 tly lower in patients with ABS compared with post-menopausal controls (p < 0.05).

6 ncreased in patients with ABS, compared with post-menopausal controls, following acute mental stress

7 ute mental stress in patients with MI versus post-menopausal controls.

8 and PR isoform expression in normal pre- and post-menopausal endometrium, well-differentiated endomet

9 d bone mass through weight-bearing exercise, post-menopausal ERT, and adequate calcium intake.

10 r being hospitalized or diagnosed with ABS), post-menopausal female controls (n = 12), and female pat

11 levels were low in the majority of males and post-menopausal females, but within normal limits for pr

12 's health, such as in oral contraception and post-menopausal hormone therapy.

13 y was a significant risk factor among women; post-menopausal hormones use was only associated with an

14 A post-menopausal hot flush consists of profuse physiologi

15 f physiological symptoms that occur during a post-menopausal hot flush.

16 Grandmother Hypothesis to simulate how human post-menopausal longevity could have evolved as ancestra

17 icrobial-dose-doxycycline (SDD) treatment of post-menopausal osteopenic women significantly reduced p

18 128 post-menopausal osteopenic women with chronic periodonti

19 above both eroded and formative surfaces in post-menopausal osteoporosis patients, and that this abs

20 sing humanized IL-27 toward the treatment of post-menopausal osteoporosis.

21 remodeling in a widespread disease, such as post-menopausal osteoporosis.

22 s are therapeutic agents in the treatment of post-menopausal osteoporosis.

23 lso improved bone strength in a rat model of post-menopausal osteoporosis.

24 reatment of osteopenic conditions, including post-menopausal osteoporosis.

25 ogen deficiency, replicating many aspects of post-menopausal osteoporosis.

26 usted p-value = 0.015) and more likely to be post-menopausal (p-value = 0.004; BH-adjusted p-value =

27 nificantly shorter survival, specifically in post-menopausal patients with advanced and terminal stag

28 When matched the participants by age, post-menopausal status was still associated with a highe

29 Increasing age and post-menopausal status were associated with the presence

30 gulates metabolic physiology, highlighted by post-menopausal temperature dysregulation (hot flashes),

31 n independently influenced oral bone loss in post-menopausal women aged <70 years.

32 Between 2001 and 2005, a total of 202 638 post-menopausal women aged 50-74 years were randomly ass

33 th Initiative Hormone Trials enrolled 27,347 post-menopausal women ages 50 to 79 years.

34 cardiomyopathy that occurs predominantly in post-menopausal women and may be triggered by acute ment

35 tion is critical for designing therapies for post-menopausal women and others with dementia.

36 onary heart disease (CHD) risk prediction in post-menopausal women compared with assessment using tra

37 Participants were 84,537 post-menopausal women from the WHI (Women's Health Initi

38 Post-menopausal women have an increased risk of developi

39 Men and post-menopausal women have greater risk of developing co

40 noni), enhanced performances in athletes and post-menopausal women in clinical studies.

41 therapy (HRT) has been used increasingly by post-menopausal women in western countries.

42 se, risk factors for sudden cardiac death in post-menopausal women include African-American race, hig

43 Post-menopausal women more frequently have many traditio

44 ex/hormone status was grouped as: 1) men; 2) post-menopausal women not receiving hormone replacement

45 d risk of future systemic bone loss in these post-menopausal women not yet on anti-osteoporotic drugs

46 With the aging U.S. population, post-menopausal women now have the greatest population b

47 in two measures of olfactory function in 14 post-menopausal women receiving estrogen replacement the

48 en not receiving hormonal contraceptives; 4) post-menopausal women receiving hormone replacement ther

49 ng estrogen replacement therapy (ERT) and 48 post-menopausal women receiving no such therapy.

50 therapy to prevent cardiovascular disease in post-menopausal women remains contentious.

51 CV complications are more severe in men and post-menopausal women than in pre-menopausal women.

52 window hypothesis, i.e., that the brains of post-menopausal women ultimately lose their ability to r

53 In a preference trial, 18 symptomatic post-menopausal women underwent a passive heat stress to

54 ouble-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one

55 tase inhibitor administered after surgery to post-menopausal women with hormonally responsive breast

56 One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic os

57 d, double-blind, placebo-controlled trial of post-menopausal women with serum 25-hydroxyvitamin D con

58 INTERPRETATION: Among post-menopausal women with severe osteoporosis, the risk

59 n a preference-controlled trial involving 21 post-menopausal women, 16 weeks of supervised moderate i

60 with increased incidence of breast cancer in post-menopausal women, and with increased mortality from

61 n reduces the risk of Alzheimer's disease in post-menopausal women, beta-amyloid (Abeta) burden in an

62 ascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of

63 n and -12.5 ml/yr (95% CI, -16.2 to -8.9) in post-menopausal women, compared with women menstruating

64 ssue, which are major sources of estrogen in post-menopausal women, could up-regulate hPRLR gene expr

65 was associated with decreasing HF risk among post-menopausal women, even in the absence of antecedent

66 declined more rapidly among transitional and post-menopausal women, in particular for FVC, beyond the

67 This cross-sectional study of 1256 post-menopausal women, recruited from the Buffalo center

68 In post-menopausal women, shorter total reproductive durati

69 In hyperlipidemic post-menopausal women, statin therapy induced EAT regres

70 In post-menopausal women, the attenuation of PP amplificati

71 y benefits the outcome of cerebral stroke in post-menopausal women, we designed the present study to

72 cidence of HF hospitalization among healthy, post-menopausal women, whereas multivariable adjustment

73 erine (and tail) arteries from aged mice and post-menopausal women.

74 rdiovascular and bone remodelling markers in post-menopausal women.

75 e risk factors for breast cancer in pre- and post-menopausal women.

76 th increased bone resorption in osteoporotic post-menopausal women.

77 ne and cerebral ischemia incidents/impact in post-menopausal women.

78 onary artery calcium (CAC) in hyperlipidemic post-menopausal women.

79 SCD) and to identify risk factors for SCD in post-menopausal women.

80 is and telangiectasias were conducted on 410 post-menopausal women.

81 m bone-resorption biomarkers in subgroups of post-menopausal women.

82 We included 26,160 healthy, post-menopausal women.

83 of ovarian hormone intervention in peri- and post-menopausal women.

84 ent heart failure (HF) hospitalization among post-menopausal women.

85 men and -5.2 ml/yr (95% CI, -8.3 to -2.0) in post-menopausal women.

86 was added to predictive models using TRFs in post-menopausal women.

87 centiles of a population-based study of 3100 post-menopausal women.

88 of alveolar crestal height and tooth loss in post-menopausal women.